Screener
G&A at other companies
Other financials
Where this comes from
Reported directly by Kymera Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:GeneralAndAdministrativeExpense.
The source filing: Kymera Therapeutics’s 10-Q, filed August 5, 2026.
- Filed
- Aug 5, 2026, 7:15 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-333849
| Line item | Three Months Ended June 30, 2026 | Three Months Ended June 30, 2025 | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|---|---|
| Collaboration revenue | $65,000 | $11,476 | $99,365 | $33,576 |
| Operating expenses: | ||||
| Research and development | $119,481 | $78,388 | $217,644 | $158,643 |
| General and administrative | 21,126 | 17,645 | 41,484 | 33,916 |
| Total operating expenses | 140,607 | 96,033 | 259,128 | 192,559 |
| Loss from operations | (75,607) | (84,557) | (159,763) | (158,983) |
| Other income (expense): | ||||
| Interest and other income | 14,477 | 8,051 | 29,459 | 16,968 |
Item 1. Financial Statements.
FAQ
- What is Kymera Therapeutics's G&A?
- Kymera Therapeutics (KYMR) reported G&A of $21.13M in Q2 2026.
- How has Kymera Therapeutics's G&A changed year-over-year?
- Kymera Therapeutics's G&A increased by 19.7% year-over-year, from $17.65M to $21.13M.
- What is the long-term trend for Kymera Therapeutics's G&A?
- Over 4 years (2021 to 2025), Kymera Therapeutics's G&A has grown at a 17.0% compound annual growth rate (CAGR), from $36.35M to $68.19M.
- What does G&A mean?
- Overhead costs not directly tied to production or sales — corporate management, legal, accounting, office rent, insurance, and other administrative functions.
Ask your AI about Kymera Therapeutics's g&a.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude